Citations

Clear

1446 citation(s) found for "Howard, F".

Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition
Krishnan, Anuradha, Viker, Kimberly, Sanderson, Schuyler O., Cazanave, Sophie C. , McConico, Andrea L., Masuoko, Howard, Charlton, Michael , Gores, Gregory J.

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | August 12, 2011 | Volume: 301 | Issue: 5 | Pages: G825-G834

10.1152/ajpgi.00145.2011 | PMID 21836057 Get It

Although there are small animal platforms that recapitulate some of the histological features of nonalcoholic fatty liver disease, there are no small animal models of nonalcoholic steatohepatitis (NASH) with consistent hepatocellular ballooning and progressive fibrosis that also exhibit fidelity to the human condition physiologically. We examined the metabolic and histological effects of a diet on the basis of the composition of “fast food” (high saturated fats, cholesterol, and fructose). Mice ( n = 8 in each group) were assigned to diets as follows: 1) standard chow (SC), i.e., 13% energy as fat [1% saturated fatty acids (SFA)], 2) high fat (HF), i.e., 60% energy as fat (1% SFA), and 3) fast food (FF), i.e., 40% energy as fat (12% SFA, 2% cholesterol). All three diets were supplemented with high fructose. All diets produced obesity. The HF and FF diets produced insulin resistance. Liver histology was normal in animals fed the SC diet. Steatohepatitis with pronounced ballooning and progressive fibrosis (stage 2) was observed in mice fed the FF diet. Although the HF diet produced obesity, insulin resistance, and some steatosis; inflammation was minimal, and there was no increase in fibrosis. The FF diet produced a gene expression signature of increased fibrosis, inflammation, and endoplasmic reticulum stress and lipoapoptosis. A diet based on high cholesterol, high saturated fat, and high fructose recapitulates features of the metabolic syndrome and NASH with progressive fibrosis. This represents a novel small animal model of fibrosing NASH with high fidelity to the human condition. These results highlight the contribution of dietary composition to the development of nonalcoholic fatty liver disease and NASH.
Self-Reported Atrial Fibrillation and Risk of Stroke in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study
Soliman, Elsayed Z. , Howard, George , Cushman, Mary , Muntner, Paul , Pullicino, Patrick M., McClure, Leslie A. , Howard, Virginia J. , Meschia, James F. , Judd, Suzanne E. , Howard, Virginia J , Howard, George

Mayo Clinic

Stroke | August 5, 2011 | Volume: 42 | Issue: 10 | Pages: 2950-2953

10.1161/strokeaha.111.621367 | PMID 21817138 Get It

Background and Purpose— We compared the associations of self-reported atrial fibrillation (AF) and ECG-detected AF with incident stroke in the Risk of Stroke in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Methods— In this analysis, 27 109 participants aged 45 years or older without previous stroke were included. Stroke cases were identified and adjudicated during an average of 4.4 years of follow-up. Cox proportional hazards analysis was used to calculate hazard ratios (HR) of self-reported AF, ECG-detected AF, and AF detected by either method with incident stroke. We also examined the predictive ability of the Framingham Stroke Risk Score (FSRS) when the component AF was defined by different methods. Results— After adjustment for components of the FSRS, self-reported AF, ECG-detected AF, and AF by either method were predictive of incident stroke (HR, 1.41; 95% CI, 1.05–1.88; HR, 1.90; 95% CI, 1.10–3.27; HR, 1.53; 95% CI, 1.16–2.01, respectively). When self-report, ECG, or either method, separately, were considered as the method of AF ascertainment in the FSRS, the HR per 1% increase in the FSRS were identical across AF ascertainment methods (HR, 1.04; 95% CI, 1.03–1.04; HR, 1.04; 95% CI, 1.04–1.05; HR, 1.04; 95% CI, 1.03–1.04; respectively). Conclusions— Self-reported AF is a strong predictor of stroke that can be used interchangeably or in combination with ECG-detected AF in stroke risk prediction models.
O1‐01‐08: Development of a genetic education and genetic risk disclosure protocol for individuals with mild cognitive impairment
Lautenbach, Denise, Karlawish, Jason , Roberts, J. Scott , Bradbury, Margaret, Uhlmann, Wendy R. , Petersen, Ronald C. , Fafowora, Tolulope, Harkins, Kristin , Zausmer, Lindsay, Green, Robert C. , Obisesan, Thomas O. , Cupples, L. Adrienne , Wood, Elisabeth McCarty

Mayo Clinic

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_3 | Pages: No page available

10.1016/j.jalz.2011.05.230 Get It

P3‐006: Neurons during early development are highly vulnerable to TDP‐43 dysregulation
Yang, Baoli, Farnham, Mackenzie, Wuertzer, Charles A., D’Alton, Simon , Howard, John , Lin, Wen-Lang, Scott, Brittany, Jurasic, Michael, Yu, Xin , Bailey, Rachel M. , Petrucelli, Leonard , Lewis, Jada , Cannon, Ashley , Knight, Joshua A. , Zhang, Yong‐Jie , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_15 | Pages: No page available

10.1016/j.jalz.2011.05.1445 Get It

P3‐003: Effect of strain background on pathology progression in tau mouse model
Bailey, Rachel M. , Howard, John , Lewis, Jada , Knight, Joshua A. , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_15 | Pages: No page available

10.1016/j.jalz.2011.05.1442 Get It

Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
Chen, Alice P. , Ji, Jiuping , Zhang, Yiping , Ames, Matthew M. , Jia, Lee , Weil, Marcie, Speranza, Giovanna, Murgo, Anthony J., Kinders, Robert J. , Wang, Lihua , Parchment, Ralph E. , Carter, John , Stotler, Howard, Rubinstein, Larry , Hollingshead, Melinda G. , Melillo, Giovanni, Bonner, William, Tomaszewski, Joseph E. , Doroshow, James H. , Kummar, Shivaani , Reid, Joel M. , Pommier, Yves G. , Rubinstein, Larry V

Mayo Clinic

Cancer Research | July 28, 2011 | Volume: 71 | Issue: 17 | Pages: 5626-5634

10.1158/0008-5472.can-11-1227 | PMID 21795476 Get It

Abstract A phase I trial of ABT-888 (veliparib), a PARP inhibitor, in combination with topotecan, a topoisomerase I–targeted agent, was carried out to determine maximum tolerated dose (MTD), safety, pharmacokinetics, and pharmacodynamics of the combination in patients with refractory solid tumors and lymphomas. Varying schedules and doses of intravenous topotecan in combination with ABT-888 (10 mg) administered orally twice a day (BID) were evaluated. Plasma and urine pharmacokinetics were assessed and levels of poly(ADP-ribose) (PAR) and the DNA damage marker γH2AX were measured in tumor and peripheral blood mononuclear cells (PBMC). Twenty-four patients were enrolled. Significant myelosuppression limited the ability to coadminister ABT-888 with standard doses of topotecan, necessitating dose reductions. Preclinical studies using athymic mice carrying human tumor xenografts also informed schedule changes. The MTD was established as topotecan 0.6 mg/m2/d and ABT-888 10 mg BID on days one to five of 21-day cycles. Topotecan did not alter the pharmacokinetics of ABT-888. A more than 75% reduction in PAR levels was observed in 3 paired tumor biopsy samples; a greater than 50% reduction was observed in PBMCs from 19 of 23 patients with measurable levels. Increases in γH2AX response in circulating tumor cells (CTC) and PBMCs were observed in patients receiving ABT-888 with topotecan. We show a mechanistic interaction of a PARP inhibitor, ABT-888, with a topoisomerase I inhibitor, topotecan, in PBMCs, tumor, and CTCs. Results of this trial reveal that PARP inhibition can modulate the capacity to repair topoisomerase I–mediated DNA damage in the clinic. Cancer Res; 71(17); 5626–34. ©2011 AACR.
Neurovascular Complications of Dialysis and Transplantation
HARRIS, LCDR ROBERT D., Campbell, J. Keith, Howard, F , Woods, John E., Anderson, Carl F., Sayre, George P.

Mayo Clinic

Stroke | June 17, 2011 | Volume: 5 | Issue: 6 | Pages: 725-729

10.1161/01.str.5.6.725 | PMID 4610914 Get It

Dialysis and transplantation are now standard treatments for end-stage renal failure. Often, neurologists are consulted regarding the neurological complications of these therapeutic procedures. In addition to previously reported complications, neurovascular disease is being recognized as a cause of mortality and morbidity in these patients. We report two cases of apparent thromboembolic stroke in young patients with renal failure -- one treated by dialysis and the other by renal transplantation. The risk factors of both dialysis and transplant are identified and data from the American College of Surgeons/National Institutes of Health Transplant Registry are reviewed.
Abstract PD10-02: Round-Robin Review of HER2 Testing in the Context of Adjuvant Therapy for Breast Cancer (NCCTG N9831/BCIRG006/BCIRG005)
Perez, EA, Dueck, A. C. , Press, MF, Chen, B, Jenkins, RB , Kim, Choon Kwan , Wiktor, AE, Meyer, R., Villalobos, Itzel Bustos, Finnigan, Melanie, Zujewski, J., Shing, Mona, Stern, Howard M., Lingle, WL, Reinholz, MM, Slamon, DJ., Paik, Soonmyung , Ketterling, Rhett P. , Buyse, Marc

Mayo Clinic

Cancer Research | April 27, 2011 | Volume: 70 | Issue: 24_Supplement | Pages: PD10-02-PD10-02

10.1158/0008-5472.sabcs10-pd10-02 Get It

Abstract Identification of HER2 as an important cellular marker in the biology and treatment of breast cancer has highlighted the importance of reliable testing methodology. Controversy exists regarding type of test, reliability, definition of positivity, and which test may best predict for patient (pt) efficacy to anti-HER2 therapies. Purpose: To determine the concordance between HER2 results by 3 central laboratories, impact of round-robin adjudication of discordant cases, and heterogeneity in HER2 results using specimens from 3 adjuvant trials where HER2 testing was performed by local and central laboratories for enrollment. Methods: We performed a blinded round-robin exchange of randomly sampled, HER2-normal (IHC-& FISH-) and HER2-positive breast tumors among 3 central laboratories (NCCTG, BCIRG and NSABP) for confirmatory HER2 testing. The 3 laboratories performed immunohistochemistry (IHC) for HER2 using the HercepTest kit (Dako, Carpenteria, CA) and fluorescence in situ hybridization (FISH) for HER2 using the PathVysion HER2 DNA probe kit/HER2/CEN17 probe mixture (Abbott Molecular, Des Plaines, IL) on 389 tumor specimens obtained from N9831/BCIRG006 (37 IHC+/FISH+, 33 IHC+/FISH-, 36 IHC-/FISH+, 62 IHC-& FISH-) and BCIRG005 (96 IHC-& FISH-); 123 cases had ≥2 blocks examined from the same pt. HER2 positivity was defined according to FDA-approved guidelines used in the clinical trials (IHC+: 3+ complete membrane staining in >10% cells; FISH+: HER2/CEN17 ratio ≥2.0). The HER2 status (IHC: 3+ vs 0-2+; FISH: amplified vs not) for each block was independently determined at each site; discordant IHC and FISH cases were adjudicated at a face-to-face meeting. Results: Independent reads were concordant across pathologists in IHC status in 351/381 (92%) cases and in FISH status in 343/373 (92%) cases. Upon adjudication, a consensus was reached on 16 and 18 of the discordant IHC and FISH cases, respectively. Among 96 BCIRG005 cases, IHC-and FISH-were confirmed in the primary block in all 96 cases. Among 59 evaluable N9831 HER2-normal cases, IHC-and FISH-were confirmed in the primary block in 57 (97%) cases (but another block tested HER2+ for 4 cases). Among 102 N9831/BCIRG006 HER2+ cases, HER2 positivity was confirmed in the primary block in 73 (72%) cases. Among 118 cases with IHC results for > 1 block, the adjudicated IHC result agreed across blocks in 106 (90%) cases. Among 113 cases with FISH results for >1 block, the adjudicated FISH result agreed in 107 (95%) cases. Among 53 N9831 HER2-normal cases adjudicated as IHC-& FISH-(although they all had a previous local HER2+ test), there was significant improvement in disease-free survival associated with trastuzumab given concurrently with paclitaxel after doxorubicin and cyclophosphamide compared to chemotherapy alone (HR=0.31, 95% CI 0.11-0.91; A 23 pts, 10 events; C 30 pts, 5 events). Conclusions: Excellent agreement (96%) was observed among the pathologists at adjudication, suggesting that standardized methods improve assay proficiency. HER2 heterogeneity across blocks was observed more at the protein than at the gene level. In the small subset of N9831 pts adjudicated as HER2-normal trastuzumab benefit was observed. This work was supported by NCI and Genentech. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr PD10-02.
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Albert, Marilyn S. , DeKosky, Steven T. , Dickson, Dennis W. , Dubois, Bruno , Feldman, Howard , Fox, Nick C. , Gamst, Anthony, Jagust, William J. , Petersen, Ronald C. , Snyder, Peter J. , Carrillo, María C. , Thies, Bill, Phelps, Creighton H., Holtzman, David M. , Dickson, Dennis W , Fox, Nick C , Feldman, Howard H

Mayo Clinic

Alzheimer's & Dementia | April 22, 2011 | Volume: 7 | Issue: 3 | Pages: 270-279

10.1016/j.jalz.2011.03.008 | PMID 21514249 Get It

The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer's disease (AD), referred to in this article as mild cognitive impairment due to AD. The workgroup developed the following two sets of criteria: (1) core clinical criteria that could be used by healthcare providers without access to advanced imaging techniques or cerebrospinal fluid analysis, and (2) research criteria that could be used in clinical research settings, including clinical trials. The second set of criteria incorporate the use of biomarkers based on imaging and cerebrospinal fluid measures. The final set of criteria for mild cognitive impairment due to AD has four levels of certainty, depending on the presence and nature of the biomarker findings. Considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis for use in community settings.